RXi Pharmaceuticals Corp. (NASDAQ:RXII) shares were down 2.5% during mid-day trading on Thursday . The stock traded as low as $2.23 and last traded at $2.31, with a volume of 52,835 shares. The stock had previously closed at $2.37.

Several research analysts have recently issued reports on RXII shares. Zacks Investment Research upgraded RXi Pharmaceuticals Corp. from a “hold” rating to a “buy” rating and set a $2.50 price objective for the company in a research note on Friday, June 10th. HC Wainwright started coverage on RXi Pharmaceuticals Corp. in a research report on Tuesday, June 7th. They set a “buy” rating and a $3.50 price target for the company.

The company’s market capitalization is $15.35 million. The firm’s 50-day moving average is $2.41 and its 200 day moving average is $2.51.

RXi Pharmaceuticals Corp. (NASDAQ:RXII) last released its quarterly earnings data on Thursday, August 11th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.02. During the same period last year, the firm earned ($0.50) EPS. On average, equities analysts predict that RXi Pharmaceuticals Corp. will post ($1.50) EPS for the current year.

RXi Pharmaceuticals Corporation is a biotechnology company focused on discovering and developing therapies addressing high unmet medical needs, primarily in the areas of dermatology and ophthalmology. The Company’s development programs are based on its siRNA technology and immunotherapy agents. Its clinical development programs include self-delivering RNAi (sd-rxRNA) compounds for the treatment of dermal and retinal scarring, and an immunodulating agent, Samcyprone, for the treatment of such disorders as alopecia areata, warts and cutaneous metastases of melanoma.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.